Abstract
To effectively inhibit the growth of breast cancer cells (MDA-MB-231 cells) by the combination method of chemotherapy and magnetic hyperthermia, we fabricated a biomimetic drug delivery (CSiFePNs) system composed of mesoporous silica nanoparticles (MSNs) containing superparamagnetic ferroferric oxide and Paclitaxel (PTX) coated with MDA-MB-231 cell membranes (CMs). In the in vitro cytotoxicity tests, the MDA-MB-231 cells incubated with CSiFePNs obtained IC50 value of 0.8 μgL−1, 3.5-fold higher than that of SiFePNs. The combination method of chemotherapy and magnetic hyperthermia can effectively inhibit the growth of MDA-MB-231 cells.
Highlights
In recent years, magnetic hyperthermia therapy has been widely used in the cancer treatment in vivo because of a few excellent advantages such as heat-induced properties, chemical stability, targeting ability and so on[13,16,17,18,19,20,21]
mesoporous silica nanoparticles (MSNs)/Fe3O4 was synthesized by a self-assembly method, in which Fe3O4 was located in the core of MSN
We prepared a biomimetic nanodrug delivery system with cell membranes to inhibit the growth of MDA-MB-231 cells by using the combination method of chemotherapy and magnetic hyperthermia
Summary
The average size and zeta-potential both demonstrate that SiFePNs were successfully coated by CMs. As can be seen from Fig. S1, the H2 hysteresis loops of MSN belongs to the IV isotherms of the IUPAC classification, confirming the typical mesoporous structure of MSN. The pore volume (0.25 cm3/g) and surface area (218.34 m2/g) of SiFePNs are significantly reduced compared with those (1.19 cm3/g and 845.93 m2/g) of MSN. This may be because the pore space is occupied by the drugs and Fe3O4. The FT-IR spectra of CSiFePNs are significantly similar to that of the cell membrane for CMs. Two weaker absorption peaks (1244 cm−1 and 1083 cm−1) of CMs still exist in the FT-IR spectra of CSiFePNs (1241 cm−1 and 1095 cm−1).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.